Press Releases
Company News
View Summary Medivation Announces Participation at Upcoming Investor Conferences
Oct 30, 2013
PDF 9.6 KB Add to Briefcase
View Summary Medivation Announces Third Quarter 2013 Financial Results Teleconference on November 12, 2013
Oct 28, 2013
PDF 9.1 KB Add to Briefcase
View Summary Medivation and Astellas Announce the Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naive Patients With Advanced Prostate Cancer
Oct 22, 2013
PDF 65.5 KB Add to Briefcase
View Summary New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
Sep 26, 2013
PDF 819.5 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Aug 27, 2013
PDF 9.4 KB Add to Briefcase
View Summary Medivation Reports Second Quarter Financial Results and Provides Corporate Update
Aug 8, 2013
PDF 75.5 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Aug 6, 2013
PDF 9.4 KB Add to Briefcase
View Summary Medivation Announces Second Quarter 2013 Financial Results Teleconference on August 8, 2013
Jul 25, 2013
PDF 9.3 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conference
Jun 27, 2013
PDF 9.4 KB Add to Briefcase
View Summary Medivation and Astellas Initiate Phase 2 Study of Enzalutamide in Breast Cancer Patients
Jun 26, 2013
PDF 64.3 KB Add to Briefcase
View Summary XTANDI™ (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer
Jun 24, 2013
PDF 64.5 KB Add to Briefcase
View Summary Medivation Voted Among Top Workplaces in the SF Bay Area
Jun 18, 2013
PDF 11.6 KB Add to Briefcase
View Summary XTANDI(R) (Enzalutamide) Capsules Receives Health Canada Approval for Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Previously Treated With Docetaxel
Jun 3, 2013
PDF 58.9 KB Add to Briefcase
View Summary Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan
May 24, 2013
PDF 60.3 KB Add to Briefcase
View Summary Medivation Names Stephen Kelsey Senior Vice President of New Projects
May 13, 2013
PDF 10.1 KB Add to Briefcase
View Summary Medivation Reports First Quarter Financial Results and Provides Corporate Update
May 9, 2013
PDF 72.1 KB Add to Briefcase
View Summary Medivation Announces Participation at Upcoming Investor Conferences
May 6, 2013
PDF 9.6 KB Add to Briefcase
View Summary Medivation Elects Wendy L. Yarno to Board of Directors
Apr 29, 2013
PDF 9.5 KB Add to Briefcase
View Summary POSITIVE CHMP OPINION FOR XTANDI (ENZALUTAMIDE) IN ADVANCED PROSTATE CANCER
Apr 26, 2013
PDF 64.6 KB Add to Briefcase
View Summary Medivation Announces First Quarter 2013 Financial Results Teleconference on May 9, 2013
Apr 25, 2013
PDF 9.6 KB Add to Briefcase
Showing 41-60 of 315 Page: 1 2 3 4 5 6 7 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Top